| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| Bloomberg ticker | ALKB DC |
| ISIN code | DK0061802139 |
| Industry group | Pharmaceuticals and biotechnology |
| Aligned with SDGs |
ALK-Abello is a Danish company focused on the development of allergy treatments products. The company is currently the leading player in the global allergy immunotherapy (AIT) market with an estimated market share of 40%. Active in 46 countries, approximately 2.4 million patients were treated with ALK-Abello products in 2023. The company was founded in 1923, employs 2,900 people and is headquartered in Horsholm, Denmark.
Investment rationale
ALK improves access to diagnostics and treatments for respiratory allergies. In Europe, approximately 87 million individuals suffer from allergies, with one-fourth of children experiencing allergic conditions. Many children suffer from allergy-related sleep and cognitive function impairments, reduced academic performance and restricted ability to participate in sport and other activities. ALK promotes greater access to allergy care by covering additional patient populations and is preparing the launch of allergy treatments for children in Europe and North America (already doing so in Japan).
Besides the positive impact of its products and promoting greater access to allergy care, ALK also engages systematically in educational activities, training and dialogue with healthcare professionals to enhance insights into diagnosis and treatment of allergic disease. By 2030, ALK commits to educate 200,000 healthcare professionals and to establish partnerships in allergy treatment and immunotherapy to raise awareness about patient care and product safety.